06/11/20
Women in IBD Awards recognize the valuable contributions of outstanding women leaders in IBD across two categories
TORONTO, Ontario and KIRKLAND, Quebec, November 9, 2020 ‒ Crohn’s and Colitis Canada and Pfizer Canada are pleased to announce the two recipients of the 2020 outstanding Women leaders in inflammatory bowel disease (IBD) research awards.
Congratulations to Dr. Elena Verdu in the category of Outstanding Researcher and to Dr. Vivian Huang in the category of Emerging Researcher. Dr. Verdu is recognized for her leadership and significant contributions to IBD research with a primary interest in investigating the role of gut microbes in chronic intestinal inflammation. As an early career scientist, Dr. Huang is recognized for her outstanding contributions in understanding the impact of IBD on fertility, pregnancy, and maternal and infant outcomes.
The Women in IBD Awards recognize women who are making outstanding contributions to the field of IBD research across two categories: (1) Outstanding Researcher that recognizes the exceptional contributions by an inspirational leading female researcher in IBD, and (2) Emerging Researcher that recognizes the contributions by a female IBD researcher in the early stages of her career. Nominations are reviewed and selected based on the nominee’s impact on the Canadian IBD community, contributions to the mission of Crohn’s and Colitis Canada, and demonstration of innovation and leadership in the field of IBD. Each prestigious award provides the recipient with funding towards IBD research.
“We are thrilled to present these awards with the support of Pfizer Canada honouring women scientists in IBD research while also advancing innovative research which can improve the lives of people living with Crohn’s or colitis,” says Kate Lee, Vice-President of Research and Patient Programs, Crohn’s and Colitis Canada. “With the field of gastroenterology historically attracting fewer women in leadership roles, it is important for us to provide opportunities that encourage, recognize and reward women leaders in this field.”
“Research and development is at the heart of fulfilling Pfizer’s purpose as we work to translate advanced science and technologies into the therapies that matter most. When it comes to research and improving patient care, collaboration is key,” says Stella Ananthan, Head of Inflammation and Immunology Business Unit, Pfizer Canada. “We are proud to collaborate with Crohn’s and Colitis Canada to support these women leaders in their research endeavors that will help make innovations a reality for patients.”
ABOUT CROHN’S AND COLITIS CANADA
Crohn’s and Colitis Canada is the only national, volunteer-based charity focused on finding the cures for Crohn’s disease and ulcerative colitis and improving the lives of everyone impacted by these diseases. We are the world’s second largest health charity funder of Crohn’s and colitis research, and our patient programs and advocacy efforts support the people affected by these chronic autoimmune diseases, which cause the body to attack healthy tissue, leading to the inflammation of all or part of the gastrointestinal tract. Visit crohnsandcolitis.ca for more information and follow @getgutsycanada.
About Pfizer Canada
Pfizer Canada ULC is the Canadian operation of Pfizer Inc., one of the world's leading biopharmaceutical companies. Our diversified health care portfolio includes some of the world’s best known and most prescribed medicines and vaccines. We apply science and our global resources to improve the health and well-being of Canadians at every stage of life. Our commitment is reflected in everything we do, from our disease awareness initiatives to our community partnerships. To learn more about Pfizer Canada, visit pfizer.ca or you can follow us on LinkedIn, Facebook, Twitter or YouTube.
-30-
For more information:
Corporate Affairs Canada
Pfizer Canada Media Line: 1-866-9Pfizer (1 866 973-4937)
Crohn’s and Colitis Canada